NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Cordycepin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Generic Name
Cordycepin
DrugBank Accession Number
DB12156
Background

Cordycepin has been used in trials studying the treatment of Leukemia.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 251.2419
Monoisotopic: 251.101839307
Chemical Formula
C10H13N5O3
Synonyms
Not Available
External IDs
  • NSC-401022
  • NSC-63984
Unlock the secrets to drugging the undruggable
Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.
Download eBook
Unlock the secrets to drugging the undruggable
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Cordycepin.
AmbroxolThe risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Cordycepin is combined with Benzyl alcohol.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as purine 3'-deoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 3.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Purine 3'-deoxyribonucleosides
Direct Parent
Purine 3'-deoxyribonucleosides
Alternative Parents
6-aminopurines / Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds / Primary amines
show 3 more
Substituents
6-aminopurine / Alcohol / Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Azole / Heteroaromatic compound / Hydrocarbon derivative / Imidazole
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
adenosines, 3'-deoxyribonucleoside (CHEBI:29014)
Affected organisms
Not Available

Chemical Identifiers

UNII
GZ8VF4M2J8
CAS number
73-03-0
InChI Key
OFEZSBMBBKLLBJ-BAJZRUMYSA-N
InChI
InChI=1S/C10H13N5O3/c11-8-7-9(13-3-12-8)15(4-14-7)10-6(17)1-5(2-16)18-10/h3-6,10,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,10+/m0/s1
IUPAC Name
(2R,3R,5S)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
SMILES
[H][C@@]1(CO)C[C@@]([H])(O)[C@@]([H])(O1)N1C=NC2=C(N)N=CN=C12

References

General References
Not Available
KEGG Compound
C08431
PubChem Compound
6303
PubChem Substance
347828450
ChemSpider
6064
BindingDB
50144950
RxNav
1989289
ChEBI
29014
ChEMBL
CHEMBL305686
ZINC
ZINC000001319796
PDBe Ligand
3AD
Wikipedia
Cordycepin
PDB Entries
1fa0 / 3b4b / 3b4c / 3onf / 5m5k / 6f3p

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
1CompletedTreatmentLeukemias1somestatusstop reasonjust information to hide
1, 2Unknown StatusTreatmentRefractory TdT-Positive Leukemia1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP-0.85ALOGPS
logP-1.4Chemaxon
logS-1.4ALOGPS
pKa (Strongest Acidic)13.53Chemaxon
pKa (Strongest Basic)3.94Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area119.31 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity62.1 m3·mol-1Chemaxon
Polarizability24.15 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0a7l-9540000000-15762da69c32bc742914
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0090000000-0fa1732e9876db469db5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0920000000-292ca2478b79f800bc0c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-1900000000-d274b94c83811edfea5b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-b4bdece582615426be38
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-014r-1900000000-99c9fd8f64388c70b8dd
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0api-0900000000-b35ab8daaf1f79857ac8
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-162.8810181
predicted
DarkChem Lite v0.1.0
[M-H]-162.7247181
predicted
DarkChem Lite v0.1.0
[M-H]-155.03958
predicted
DeepCCS 1.0 (2019)
[M+H]+163.2920181
predicted
DarkChem Lite v0.1.0
[M+H]+163.6972181
predicted
DarkChem Lite v0.1.0
[M+H]+157.43515
predicted
DeepCCS 1.0 (2019)
[M+Na]+162.5900181
predicted
DarkChem Lite v0.1.0
[M+Na]+162.9512181
predicted
DarkChem Lite v0.1.0
[M+Na]+163.8565
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 21:29 / Updated at June 12, 2020 16:53